Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2019 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019

- Company to provide update on Type B meeting with FDA on Phase 3 clinical trial design for FCX-007 gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB) - - Company to...
February 06, 2019 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Present at 21st Annual BIO CEO & Investor Conference

EXTON, Pa., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
January 16, 2019 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Present at Phacilitate Leaders World 2019

EXTON, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
December 11, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation

EXTON, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
November 13, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights

- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST – - Announces patient enrollment completed in Phase 2 of Phase 1/2 clinical trial for FCX-007 for recessive dystrophic...
November 08, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights

EXTON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
October 25, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007

Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019 EXTON, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc....
September 26, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Present at Upcoming Industry and Investor Conferences

EXTON, Pa., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
September 25, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

EXTON, Pa., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
September 05, 2018 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma

EXTON, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...